Impact of blaOXA and blaNDM production on the efficacy of colistin‑based antibiotic combinations in carbapenem‑resistant Acinetobacter baumannii from a tertiary care hospital in North Kerala, India

Imagine the human body as a bustling city, and inside that city, there are tiny, invisible invaders called bacteria. Most of the time, our immune system is like a highly trained police force that keeps these invaders in check. But sometimes, the bacteria get clever. They evolve superpowers, learning to ignore the weapons we use to stop them. This is called "antibiotic resistance." Think of antibiotics as the city's special weapons—like water cannons or nets—that usually wash away or trap the bad guys. But when bacteria become "resistant," it's like they've put on invisible raincoats or learned to walk through the nets.

One of the sneakiest troublemakers is a germ called Acinetobacter baumannii. It's a master of disguise and survival, often hiding in hospitals where sick people are already weak. For a long time, doctors had a "last resort" weapon called carbapenems to fight it. But now, this germ has learned to ignore even those, becoming what scientists call "carbapenem-resistant." When the big guns stop working, doctors have to try something risky: mixing two different weapons together to see if they work better as a team than alone. It's like trying to break down a locked door by hitting it with a hammer and a sledgehammer at the same time. The big question is: does this teamwork actually work, or do the weapons just get in each other's way?

---

The Battle Plan: Mixing and Matching Weapons

In a busy hospital in North Kerala, India, a team of scientists decided to investigate this exact problem. They gathered 199 samples of the Acinetobacter germ from patients who were coughing up mucus, peeing, or had infections in their wounds. They wanted to find out two things: what kind of "superpowers" (genes) these germs had, and whether mixing specific antibiotics could actually defeat them.

First, they looked at the germs' "ID cards" to see what resistance genes they carried. They found that the most common superpower was a gene called blaOXA-23, often paired with another called blaOXA-51. A smaller group of germs also carried a gene called blaNDM, which is like a heavy-duty shield against many drugs. Out of all the samples, about 40% were the tough, carbapenem-resistant kind. When they tested these tough guys with a special chemical reaction (the CarbAcineto NP test), 87.5% of them confirmed they were indeed producing the enzymes that break down our best antibiotics.

The Great Team-Up Experiment

Next, the scientists set up a laboratory arena to test two specific team-ups. They took 50 of the toughest, carbapenem-resistant germs and challenged them with two different combinations:

1. Colistin + Meropenem: A powerful duo where Colistin is like a hammer that disrupts the outer membrane, and Meropenem is a drug that usually stops cell wall building.
2. Colistin + Tigecycline: A mix of the hammer and a different drug that stops the bacteria from making proteins.

They used a method called the "E-test," which is like placing a strip of paper soaked in medicine on a petri dish to see how far the bacteria can grow before the medicine stops them. They measured the results using a score called the FICI (Fractional Inhibitory Concentration Index). If the score was low, it meant the drugs were helping each other (Synergy). If it was high, they were fighting each other (Antagonism).

The Results: One Team Fails, the Other Has a Glimmer of Hope

The results were a bit of a shocker for the first team. When they mixed Colistin and Meropenem, the drugs didn't work together at all. In fact, in 60% of the cases, they actually made things worse! This is called "antagonism." It's like having two people trying to push a car in opposite directions; instead of moving forward, they just spin their wheels and get stuck. The study found zero cases where this combination helped.

The second team, Colistin and Tigecycline, had a slightly better, though still mixed, record. About 20% of the germs showed "synergy," meaning the two drugs worked together to kill the bacteria more effectively than either one alone. In these lucky cases, the amount of medicine needed to kill the bacteria dropped significantly. However, for the other 80% of the germs, the drugs were either indifferent (doing nothing extra) or antagonistic (making things worse).

The Genetic Mystery

The researchers also wondered: "Does the type of superpower gene the bacteria have tell us which drug mix will work?" For example, if a germ has the blaNDM gene, will it definitely fail against Colistin and Tigecycline?

The answer was a resounding "No." The study found that the specific genes (whether it was just blaOXA-23, just blaNDM, or a mix of both) did not predict the outcome. A germ with the "tough" NDM gene was just as likely to show synergy as a germ without it. This means you can't just look at the bacteria's ID card and know which drug mix will work; you have to test the specific bacteria in the lab to see how it reacts.

The Bottom Line

This study tells us that fighting these super-bugs is tricky. The popular idea of mixing Colistin with Meropenem seems to be a bad idea, as it often makes the bacteria stronger or just doesn't help. On the other hand, mixing Colistin with Tigecycline might work for some bacteria (about 1 in 5), but it's not a guaranteed win. Most importantly, the bacteria's genetic "ID card" doesn't give us a clear map of which drug mix to use. Doctors still need to test the specific germ from each patient to see what actually works, because in the world of super-bugs, what works for one might fail for another, even if they look the same on paper.